Flow Neuroscience FL-100: First FDA-Approved At-Home tDCS Headset for Depression Treatment

The first FDA-approved at-home brain stimulation device for major depressive disorder, delivering transcranial direct current stimulation (tDCS) at 2.0 mA to the prefrontal cortex through a prescription Bluetooth headset that demonstrated 2 to 3 times higher remission rates than sham treatment in clinical trials.

Presented By Our Partners

Major depressive disorder affects approximately 21 million adults in the United States and remains one of the leading causes of disability worldwide. While pharmacotherapy and psychotherapy are effective for many patients, a substantial proportion, estimated at 30 to 40 percent, do not achieve adequate response to first-line antidepressant medications. A 2023 meta-analysis published in The Lancet Psychiatry by Cipriani et al. confirmed that while 21 antidepressants are more effective than placebo, effect sizes are modest and side effects including weight gain, sexual dysfunction, and emotional blunting lead many patients to discontinue treatment (DOI: 10.1016/S2215-0366(17)30521-7).

Transcranial direct current stimulation (tDCS) has emerged as a non-pharmacological intervention that modulates cortical excitability by delivering weak electrical current through scalp electrodes. A 2020 systematic review and meta-analysis published in JAMA Psychiatry by Moffa et al. evaluated tDCS for depression across randomized controlled trials, finding that active tDCS was superior to sham for both response and remission, with the prefrontal cortex as the primary stimulation target showing the most consistent efficacy (DOI: 10.1001/jamapsychiatry.2019.3437). On December 8, 2025, the FDA approved the Flow Neuroscience FL-100 as the first at-home tDCS device for treating major depressive disorder in adults, marking a landmark regulatory decision that brings brain stimulation therapy from clinical settings into patients’ homes.

What Is the Flow Neuroscience FL-100?

The Flow Neuroscience FL-100 is a prescription Bluetooth-enabled headset that delivers transcranial direct current stimulation (tDCS) to treat moderate to severe major depressive disorder in adults. The device received FDA premarket approval (PMA) on December 8, 2025, making it the first non-drug, at-home treatment for depression cleared by the FDA.

The headset delivers a 2.0 milliampere (mA) electrical current through electrodes positioned over the left dorsolateral prefrontal cortex (DLPFC), a brain region critically involved in mood regulation, executive function, and stress response. The DLPFC shows reduced activity in neuroimaging studies of depressed individuals, and tDCS aims to increase excitability in this hypoactive region, potentially normalizing the neural circuits that contribute to depressive symptoms.

The FL-100 communicates with a companion smartphone app via Bluetooth Low Energy (BLE), which guides patients through treatment sessions, tracks adherence, and monitors treatment progress. A rechargeable 250 mAh lithium polymer battery powers the headset and provides approximately 10 to 15 treatment sessions between charges.

The FDA approval covers use as a standalone treatment or as an adjunct to antidepressant medication in patients who are not medication-resistant. This dual indication means the FL-100 can serve as a first-line non-pharmacological option for patients who prefer to avoid medication, or as an augmentation strategy for patients already on antidepressants who have not achieved full response.

The Science Behind Transcranial Direct Current Stimulation

tDCS works by passing a weak direct current (typically 1.0 to 2.0 mA) between two electrodes placed on the scalp. The current does not directly cause neurons to fire; instead, it modulates the resting membrane potential of cortical neurons beneath the anode (positive electrode) and cathode (negative electrode). Anodal stimulation generally increases cortical excitability by depolarizing the neuronal membrane toward the firing threshold, while cathodal stimulation generally decreases excitability.

In depression treatment, the anode is typically placed over the left DLPFC to increase activity in this hypoactive region, while the cathode is placed over the right DLPFC or an alternative reference location. This montage aims to correct the interhemispheric imbalance in prefrontal activity observed in depression, where the left DLPFC shows reduced activity relative to the right.

The therapeutic effects of tDCS extend beyond the immediate stimulation period. Repeated sessions induce neuroplastic changes, including long-term potentiation-like effects, altered synaptic connectivity, and changes in neurotransmitter systems (including serotonin, dopamine, and glutamate) that outlast the stimulation itself. This is why tDCS treatment protocols involve multiple sessions over weeks rather than single treatments.

The 2024 clinical trial supporting the FL-100’s FDA approval demonstrated that active tDCS produced significant improvements in depressive symptoms, with therapeutic effects appearing as early as 3 weeks into treatment. Active stimulation produced 2 to 3 times higher remission and response rates compared to sham (placebo) stimulation, providing the efficacy data the FDA required for premarket approval.

The treatment protocol for the FL-100 consists of a 12-week course: five 30-minute sessions per week for the first three weeks (the acute phase), followed by two to three 30-minute sessions per week for the remaining nine weeks (the maintenance phase). This structured protocol balances treatment intensity with the practical realities of at-home self-administration.

What the Flow Neuroscience FL-100 Does Well

The FDA approval itself is the FL-100’s most significant achievement. Brain stimulation for depression has been available in clinical settings for years (through techniques like transcranial magnetic stimulation, or TMS, which requires expensive equipment and in-office visits), but the FL-100 makes brain stimulation accessible at home with a prescription. This eliminates the time burden and cost of clinic visits, which can be prohibitive for patients who would benefit from neuromodulation.

The side effect profile of tDCS is substantially milder than pharmacotherapy. Common side effects include mild tingling or itching at the electrode sites, slight skin redness, and occasional mild headache. The absence of systemic side effects (no weight gain, no sexual dysfunction, no gastrointestinal symptoms, no drug interactions) makes tDCS an attractive option for patients who have experienced intolerable medication side effects.

The companion app provides guided treatment sessions that standardize electrode placement, stimulation parameters, and session duration, reducing the risk of user error that could affect efficacy or safety. Treatment adherence tracking and progress monitoring through the app create a digital therapeutic framework around the hardware device.

The dual indication (standalone or adjunct to medication) provides clinical flexibility. Patients and prescribers can use the FL-100 as a medication-free option for those who prefer non-pharmacological treatment, or as an augmentation strategy to boost the efficacy of existing antidepressant therapy.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The prescription requirement, while adding a step for access, ensures medical oversight of a brain stimulation device and appropriate patient selection, which is important for safety and regulatory compliance.

Pricing, Access, and Practical Realities

The Flow Neuroscience FL-100 is estimated to retail between $500 and $800 in the United States. Flow Neuroscience plans to launch in the second quarter of 2026. Insurance coverage details are being finalized, with announcements expected in early 2026.

For comparison, in-clinic TMS treatment for depression typically costs $6,000 to $12,000 for a full treatment course (30 to 36 sessions), though insurance increasingly covers this for treatment-resistant patients. The FL-100’s price point, even without insurance coverage, represents a fraction of TMS cost while delivering stimulation to the same brain target (left DLPFC).

The device requires a prescription from a licensed healthcare provider. Patients cannot self-prescribe or purchase the FL-100 over the counter. The prescription pathway ensures appropriate diagnosis (confirming MDD), ruling out contraindications (such as implanted metallic devices in the head, epilepsy history, or certain neurological conditions), and establishing medical oversight of the treatment course.

Each treatment session lasts 30 minutes, and the acute phase requires five sessions per week. Users should plan for approximately 2.5 hours per week of treatment time during the first three weeks, reducing to 1 to 1.5 hours per week during the maintenance phase. While substantially less burdensome than clinic visits, this time commitment requires consistent daily adherence for optimal outcomes.

The 250 mAh battery provides approximately 10 to 15 sessions per charge, meaning users will charge the headset approximately once every 2 to 3 weeks during the maintenance phase and more frequently during the intensive acute phase.

Who It Is Best For

The Flow Neuroscience FL-100 is best suited for adults with moderate to severe major depressive disorder who want a non-pharmacological treatment option or need augmentation of existing antidepressant therapy. The FDA approval specifically covers patients who are not medication-resistant, meaning the device is positioned for earlier-line use rather than as a last-resort option.

Patients who have experienced intolerable side effects from antidepressant medications (weight gain, sexual dysfunction, emotional blunting, gastrointestinal disturbance) represent a primary population. The FL-100 offers a treatment modality with a fundamentally different and milder side effect profile.

Individuals who prefer non-pharmacological approaches to mental health treatment, whether due to personal preference, medication interactions with other conditions, pregnancy considerations, or philosophical orientation, gain a FDA-approved option that was previously unavailable at home.

Patients who have benefited from in-clinic TMS but find the cost, time commitment, and travel burden of clinic visits unsustainable for maintenance treatment may find the FL-100 a practical alternative for ongoing neuromodulation at home.

The device is not suitable for individuals with implanted metallic devices in the head (excluding dental work), history of seizures or epilepsy, certain skull defects, or other contraindications to electrical brain stimulation. It is not cleared for treatment-resistant depression, which may require different interventions. Children and adolescents are not included in the current FDA approval.

How It Compares

Against in-clinic TMS (transcranial magnetic stimulation), the FL-100 offers dramatically lower cost ($500 to $800 vs. $6,000 to $12,000), home-based convenience versus clinic visits, and a less intensive per-session experience (30 minutes of mild tingling versus louder, more noticeable magnetic pulses). TMS has a larger evidence base and is cleared for treatment-resistant depression, giving it advantages in more severe or refractory cases.

Against consumer tDCS devices (various unregulated devices available online for $100 to $400), the FL-100’s FDA approval provides regulatory validation of safety and efficacy that no consumer device can claim. Unregulated tDCS devices lack standardized electrode placement, validated stimulation parameters, and clinical trial data for depression, making them substantially riskier propositions.

Against antidepressant medications (SSRIs, SNRIs, atypicals), the FL-100 offers a non-systemic treatment with no drug interactions, no withdrawal effects, and no pharmacological side effects. Medications offer the convenience of daily pill-taking versus 30-minute device sessions, and have decades of clinical evidence across larger populations. The FL-100 may work best as a complement to medication rather than a replacement for many patients.

Against psychotherapy (CBT, interpersonal therapy), the FL-100 addresses biological rather than psychological mechanisms of depression. The two approaches are likely complementary rather than competitive, as they target different aspects of the disorder. Combining tDCS with psychotherapy is an active area of research.

Limitations and Open Questions

The long-term efficacy and safety of at-home tDCS beyond the clinical trial duration require ongoing monitoring. While the 12-week trial data supported FDA approval, questions about maintenance treatment duration, relapse rates after discontinuation, and multi-year safety profiles remain areas for future research.

Proper electrode placement is critical for tDCS efficacy. In clinical settings, trained technicians ensure precise electrode positioning. At-home use relies on the patient following app-guided instructions, and even small deviations in electrode placement can alter the brain regions receiving stimulation. The practical accuracy of self-administered electrode placement in real-world conditions is an important question.

The FDA approval excludes treatment-resistant depression, which affects a significant proportion of MDD patients. Patients who have failed multiple medication trials may be the most motivated to try neuromodulation but are outside the current indication.

Adherence to the treatment protocol (particularly the five sessions per week during the acute phase) requires substantial patient motivation and discipline. Without the external structure of clinic appointments, at-home adherence may be lower than clinical trial adherence, potentially reducing real-world efficacy.

Insurance coverage uncertainty could limit accessibility. If the FL-100 is not covered by insurance initially, the $500 to $800 out-of-pocket cost, while modest compared to TMS, may be a barrier for patients who already face financial constraints related to their depression.

What This Means for Your Health

The FDA approval of the Flow Neuroscience FL-100 represents a paradigm shift in depression treatment: for the first time, patients can access a validated brain stimulation therapy at home with a prescription, bypassing the cost and logistical barriers of clinic-based neuromodulation. This expands the treatment toolkit for major depressive disorder beyond the pharmacotherapy-psychotherapy dyad that has defined care for decades.

Within Healthcare Discovery‘s Five Pillars framework, the FL-100 connects most directly to Mindset, the pillar encompassing cognitive resilience, emotional regulation, and mental health. Depression disrupts every other pillar: it impairs sleep quality, reduces motivation for movement, degrades nutritional choices, and dysregulates the stress responses that breathwork practices aim to modulate. By addressing depression through neuromodulation, the FL-100 may create cascading benefits across all five pillars.

The broader significance lies in the precedent. The FDA’s approval of an at-home brain stimulation device for a major psychiatric condition signals regulatory confidence in patient self-administration of neuromodulation, which could accelerate approval pathways for similar devices targeting anxiety, PTSD, chronic pain, and other conditions where tDCS shows clinical promise.

Depression remains one of the most undertreated conditions globally, with treatment gaps driven by stigma, access barriers, medication side effects, and the time burden of therapy. A prescription device that a patient can use privately at home, with no systemic side effects and no clinic visits, removes several of these barriers simultaneously.

Frequently Asked Questions

What is the Flow Neuroscience FL-100?
The Flow Neuroscience FL-100 is the first FDA-approved at-home brain stimulation headset for treating major depressive disorder in adults. It delivers transcranial direct current stimulation (tDCS) at 2.0 mA to the left dorsolateral prefrontal cortex through a Bluetooth-connected prescription device, with a 12-week treatment protocol of 30-minute sessions.

How much does the Flow FL-100 cost?
The estimated US retail price is $500 to $800. Insurance coverage details are being finalized for 2026. The device requires a prescription from a licensed healthcare provider and is expected to launch in the second quarter of 2026.

Is tDCS safe for at-home use?
The FDA approved the FL-100 based on clinical trial data demonstrating safety and efficacy. Common side effects include mild tingling at electrode sites, slight skin redness, and occasional mild headache. The device is contraindicated in individuals with implanted metallic head devices, seizure history, or certain neurological conditions. The prescription requirement ensures medical oversight.

How effective is the Flow FL-100 for depression?
In the clinical trial supporting FDA approval, active tDCS produced 2 to 3 times higher remission and response rates compared to sham treatment, with improvements appearing as early as 3 weeks. The device is approved for moderate to severe MDD as standalone or adjunct to antidepressant medication.

How does the Flow FL-100 compare to TMS?
Both target the left dorsolateral prefrontal cortex for depression. TMS requires clinic visits (30 to 36 sessions) and costs $6,000 to $12,000. The FL-100 is used at home for $500 to $800. TMS has a larger evidence base and is cleared for treatment-resistant depression. The FL-100 is currently approved for non-treatment-resistant MDD.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.